DETAILED CORRESPONDENCE
Status of the Application
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Applicant’s preliminary amendment to the claims, filed November 3, 2025, is acknowledged. This listing of the claims replaces all prior versions and listings of the claims.
Claims 1, 3-11, 13, 15-17, 19, 20, 22, 25, 29 and 31 are pending in the application and are being examined on the merits.
Priority
This application is filed under 35 U.S.C. 371 as a national stage of international application PCT/CA2023/050889, filed June 28, 2023, which claims domestic priority under 35 U.S.C. 119(e) to U.S. provisional application no. 63/356,443, filed June 28, 2022.
Information Disclosure Statement
The information disclosure statements (IDSs) submitted on March 19, 2025 and April 8, 2026 are in compliance with the provisions of 37 CFR 1.97 and have been considered by the examiner.
Claim Objections
Claims 1, 3, 6, 11, 13, 19, 22, 25, 29, and 31 are objected to because of the following informalities:
Claims 1, 6, 11, 19, 25, and 29 are objected to in the recitation of “protein that comprises HTRA-NS protein (SEQ ID NO:3)” and in the interest of improving claim form, it is suggested that the noted phrase be amended to recite “protein comprising the amino acid sequence of SEQ ID NO: 3.”
Claims 3, 13, and 22 are objected to in the recitation of “wherein the one or more toxin(s) are from one or more pathogen(s)…further wherein the one or more pathogen(s) is Clostridioides difficile” and in the interest of improving claim form, it is suggested that the noted phrase be amended to recite “the one or more toxin(s) is/are from Clostridioides difficile.”
Claim 6 is objected to for reciting “a subject infected by Clostridioides difficile, diarrhea, or infectious colitis” and in the interest of improving claim form, it is suggested that the noted phrase be amended to recite “a subject infected by Clostridioides difficile, a subject having diarrhea, or a subject having infectious colitis.”
Claim 31 is objected to for reciting “nucleic acid encoding the protein” and in the interest of improving claim form, it is suggested that the noted phrase be amended to recite “nucleic acid comprising a nucleotide sequence encoding the protein.”
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 7-10, 19, 22, and 31 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
Claims 7 (claim 9 dependent therefrom) and 10 recite the limitation “the one or more toxin(s).” There is insufficient antecedent basis for this limitation in the claim.
Claim 8 recites the limitation “the one or more pathogen(s).” There is insufficient antecedent basis for this limitation in the claim.
Claim 19 is indefinite in the recitation of “a therapeutically effective amount of a protein…” because the claim fails to state the function which is to be achieved and more than one effect can be implied from the specification or the relevant art. See MPEP § 2173.05(c).
Claim 22 is indefinite because it depends from canceled claim 21.
Claim 31 is indefinite in the recitation of “nucleic acid encoding the protein of claim 29 (SEQ ID NO: 4)” because it is unclear as to whether “(SEQ ID NO: 4)” is intended as being limiting or merely an example or preference. If applicant intends for the recitation of “(SEQ ID NO: 4)” to be an example of or preference for a nucleic acid encoding the protein of claim 29, applicant is advised that description of examples and preferences is properly set forth in the specification rather than the claims. See MPEP § 2173.05(d).
Claim Rejections - 35 USC § 112(a)
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claims 1, 4, 6-11, 16, and 17 are rejected under 35 U.S.C. 112(a) because the specification, while being enabling for a method for treatment of Clostridioides difficile toxins TcdA, TcdB, and CDT in a subject, a method for preventing disease progression of Clostridioides difficile infection in a subject infected with Clostridioides difficile, and a method for prophylaxis of Clostridioides difficile toxin(s) TcdA and/or TcdB in a subject by administering to a subject in need thereof a therapeutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 3, does not reasonably provide enablement for a method for treatment of all toxins in a subject, a method for preventing progression of all diseases in a subject infected by Clostridioides difficile, having diarrhea, or having infectious colitis, and a method for the prophylaxis of all toxins in a subject by administering to a subject in need thereof a therapeutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 3. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.
“The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue.” In re Angstadt, 537 F.2d 498, 504, 190 USPQ 214, 219 (CCPA 1976). Factors to be considered in determining whether undue experimentation is required are summarized in In re Wands (858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)) as follows: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. See MPEP § 2164.01(a). The Factors most relevant to the instant rejection are addressed in detail below.
The nature of the invention: According to the specification, “[t]here is a need for treatment of CD that has a low failure rate and that is not labour intensive to provide” (p. 1, lines 33-34).
The breadth of the claims: Claims 1, 3-5, 16, and 17 are drawn to a method for treatment of one or more toxin(s) in a subject, the method comprising administering to the subject a therapeutically effective amount of a protein that comprises HTRA-NS protein (SEQ ID NO:3).
The recited toxin(s) is/are unlimited.
Claims 6-10 are drawn to a method for preventing disease progression in a subject infected by Clostridioides difficile, diarrhea, or infectious colitis, the method comprising administering to the subject a therapeutically effective amount of a protein comprising HTRA-NS protein (SEQ ID NO: 3).
The recited subject is infected by Clostridioides difficile, diarrhea, or infectious colitis, however, the recited disease(s) is/are unlimited.
Claims 11, 13, and 15 are drawn to a method for the prophylaxis of one or more toxin(s) in a subject, the method comprising administering to the subject a therapeutically effective amount of a protein comprising HTRA-NS protein (SEQ ID NO: 3).
The recited toxin(s) is/are unlimited.
The amount of direction provided by the inventor; The existence of working examples: The specification discloses that in mice that were infected with Clostridioides difficile (CD) and treated with HTRA, the CD toxin activity (TcdA, TcdB and CDT) was neutralized and pre-incubation of TcdA and TcdB toxins with HTRA protein resulted in degradation of both toxins in an HTRA-NS concentration dependent manner (p. 7, lines 14-19). Other than treating Clostridioides difficile toxins and infection, the specification fails to provide direction or guidance regarding treatment of other toxins and diseases as encompassed by the claims.
The state of the prior art; The level of one of ordinary skill; and The level of predictability in the art: According to MPEP 2164.03, “…what is known in the art provides evidence as to the question of predictability.” “[I]f one skilled in the art cannot readily anticipate the effect of a change within the subject matter to which that claimed invention pertains, then there is lack of predictability in the art.”
Before the effective filing date, the variability of protease specificity was known in the prior art – while some proteases are highly promiscuous and cleave a variety of substrates, others show high specificity for particular substrate sequences (see Schauperl et al., PLoS ONE 10:e0142658, 2015, 17 pages, particularly p. 2, top; cited on the attached Form PTO-892). Given the variability of protease specificity, one of skill in the art would recognize a high level of unpredictability that HTRA-NS protein of SEQ ID NO: 3 would neutralize all other toxins for treatment of all other infections and diseases.
The quantity of experimentation needed to make or use the invention based on the content of the disclosure: It was not routine in the art to screen a single protease for all other toxins and diseases that may be treated by the protease.
In view of the scope of the claims, the lack of guidance and working examples provided in the specification, the high level of unpredictability as evidenced by the art, and the amount of experimentation required, undue experimentation would be necessary for a skilled artisan to make and use the claimed invention. Applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of having the desired biological characteristics is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).
Claims 1, 4, 6-11, 16, and 17 are rejected under 35 U.S.C. 112(a) as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor had possession of the claimed invention.
MPEP 2163.II.A.2.(a).i) states, “Whether the specification shows that applicant was in possession of the claimed invention is not a single, simple determination, but rather is a factual determination reached by considering a number of factors. Factors to be considered in determining whether there is sufficient evidence of possession include the level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention”.
For claims drawn to a genus, MPEP § 2163 states the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.
MPEP § 2163 further states that “[s]atisfactory disclosure of a ‘representative number’ depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features possessed by the members of the genus in view of the species disclosed. For inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus…Instead, the disclosure must adequately reflect the structural diversity of the claimed genus, either through the disclosure of sufficient species that are ‘representative of the full variety or scope of the genus,’ or by the establishment of ‘a reasonable structure-function correlation.’ Such correlations may be established ‘by the inventor as described in the specification,’ or they may be ‘known in the art at the time of the filing date.’"
The factors considered in the Written Description requirement are (1) level of skill and knowledge in the art, (2) partial structure, (3) physical and/or chemical properties, (4) functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the (5) method of making the claimed invention. Disclosure of any combination of such identifying characteristics that distinguish the claimed invention from other materials and would lead one of skill in the art to the conclusion that the applicant was in possession of the claimed species is sufficient." MPEP § 2163.
Claims 1, 3-5, 16, and 17 are drawn to a method for treatment of a genus of toxins in a subject, the method comprising administering to the subject a therapeutically effective amount of a protein that comprises HTRA-NS protein (SEQ ID NO:3).
The genus of recited toxins is unlimited and is considered to encompass widely variant species of toxins.
Claims 6-10 are drawn to a method for preventing a genus of disease progressions in a subject infected by Clostridioides difficile, diarrhea, or infectious colitis, the method comprising administering to the subject a therapeutically effective amount of a protein comprising HTRA-NS protein (SEQ ID NO: 3).
The recited subject is infected by Clostridioides difficile, diarrhea, or infectious colitis, however, the genus of recited disease(s) is/are unlimited.
Claims 11, 13, and 15 are drawn to a method for the prophylaxis of a genus of toxins in a subject, the method comprising administering to the subject a therapeutically effective amount of a protein comprising HTRA-NS protein (SEQ ID NO: 3).
The genus of recited toxins is unlimited and is considered to encompass widely variant species of toxins.
The specification discloses that in mice that were infected with Clostridioides difficile (CD) and treated with HTRA, the CD toxin activity (TcdA, TcdB and CDT) was neutralized and pre-incubation of TcdA and TcdB toxins with HTRA protein resulted in degradation of both toxins in an HTRA-NS concentration dependent manner (p. 7, lines 14-19). Other than treating Clostridioides difficile toxins and infection, the specification fails to provide direction or guidance regarding treatment of other toxins and diseases as encompassed by the claims.
Regarding the level of skill and knowledge in the art, the variability of protease specificity was known in the prior art – while some proteases are highly promiscuous and cleave a variety of substrates, others show high specificity for particular substrate sequences (see Schauperl et al., PLoS ONE 10:e0142658, 2015, 17 pages, particularly p. 2, top; cited on the attached Form PTO-892). Given the variability of protease specificity, one of skill in the art would recognize a high level of unpredictability that HTRA-NS protein of SEQ ID NO: 3 would neutralize all other toxins for treatment of all other infections and diseases.
Given the unpredictability in the relevant art and that the methods encompass treatment of a widely variant genus of toxins and diseases and encompass prophylaxis of a widely variant genus of toxins while the specification discloses an actual reduction to practice of treating Clostridioides difficile infection and treatment or prophylaxis of toxins TcdA, TcdB, and CDT, the specification fails to sufficiently describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize that applicant was in possession of the claimed invention. As such, the specification fails to satisfy the written description requirement of 35 U.S.C. 112(a).
Examiner Comment
The closest prior art is considered to be UniProt Accession Number A6L8X8 (May 2022, 2 pages; cited on the IDS filed April 8, 2026; hereafter “UniProt”) disclosing a serine protease from Parabacteroides distasonis with amino acids 25 to 507 corresponding to amino acids 2 to 484 of instant SEQ ID NO: 3 (see Appendix for sequence alignment). There is no teaching or suggestion in the prior art of record to artificially remove amino acids 1-23 of the Parabacteroides distasonis serine protease of UniProt and add an N-terminal methionine to arrive at the amino acid sequence of instant SEQ ID NO: 3.
Conclusion
Status of the claims:
Claims 1, 3-11, 13, 15-17, 19, 20, 22, 25, 29 and 31 are pending.
Claims 1, 4, 6-11, 16, 17, 19, 22, and 31 are rejected.
Claims 3, 5, 13, 15, 20, 25, and 29 are objected to for minor informalities or for being dependent upon a rejected base claim.
No claim is in condition for allowance.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID J STEADMAN whose telephone number is (571)272-0942. The examiner can normally be reached Monday to Friday, 7:30 AM to 4:00 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MANJUNATH N RAO can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/David Steadman/Primary Examiner, Art Unit 1656
APPENDIX
AC A6L8X8;
DT 24-JUL-2007, integrated into UniProtKB/TrEMBL.
DT 24-JUL-2007, sequence version 1.
DT 28-JAN-2026, entry version 90.
DE SubName: Full=Serine protease {ECO:0000313|EMBL:ABR42142.1};
GN OrderedLocusNames=BDI_0359 {ECO:0000313|EMBL:ABR42142.1};
OS Parabacteroides distasonis (strain ATCC 8503 / DSM 20701 / CIP 104284 / JCM
OS 5825 / NCTC 11152).
OC Bacteria; Pseudomonadati; Bacteroidota; Bacteroidia; Bacteroidales;
OC Tannerellaceae; Parabacteroides.
OX NCBI_TaxID=435591 {ECO:0000313|EMBL:ABR42142.1, ECO:0000313|Proteomes:UP000000566};
RN [1] {ECO:0000313|EMBL:ABR42142.1, ECO:0000313|Proteomes:UP000000566}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=ATCC 8503 / DSM 20701 / CIP 104284 / JCM 5825 / NCTC 11152
RC {ECO:0000313|Proteomes:UP000000566};
RX PubMed=17579514; DOI=10.1371/journal.pbio.0050156;
RA Xu J., Mahowald M.A., Ley R.E., Lozupone C.A., Hamady M., Martens E.C.,
RA Henrissat B., Coutinho P.M., Minx P., Latreille P., Cordum H.,
RA Van Brunt A., Kim K., Fulton R.S., Fulton L.A., Clifton S.W., Wilson R.K.,
RA Knight R.D., Gordon J.I.;
RT "Evolution of symbiotic bacteria in the distal human intestine.";
RL PLoS Biol. 5:1574-1586(2007).
CC -!- SIMILARITY: Belongs to the peptidase S1C family.
CC {ECO:0000256|ARBA:ARBA00010541}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; CP000140; ABR42142.1; -; Genomic_DNA.
DR RefSeq; WP_005862015.1; NC_009615.1.
DR AlphaFoldDB; A6L8X8; -.
DR STRING; 435591.BDI_0359; -.
DR PaxDb; 435591-BDI_0359; -.
DR KEGG; pdi:BDI_0359; -.
DR PATRIC; fig|435591.13.peg.354; -.
DR eggNOG; COG0265; Bacteria.
DR HOGENOM; CLU_020120_1_0_10; -.
DR BioCyc; PDIS435591:G1G5A-370-MONOMER; -.
DR Proteomes; UP000000566; Chromosome.
DR GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR Gene3D; 2.30.42.10; -; 2.
DR Gene3D; 2.40.10.120; -; 1.
DR InterPro; IPR001478; PDZ.
DR InterPro; IPR025926; PDZ-like_dom.
DR InterPro; IPR036034; PDZ_sf.
DR InterPro; IPR011782; Pept_S1C_Do.
DR InterPro; IPR009003; Peptidase_S1_PA.
DR InterPro; IPR001940; Peptidase_S1C.
DR NCBIfam; TIGR02037; degP_htrA_DO; 1.
DR PANTHER; PTHR22939; SERINE PROTEASE FAMILY S1C HTRA-RELATED; 1.
DR PANTHER; PTHR22939:SF129; SERINE PROTEASE HTRA2, MITOCHONDRIAL; 1.
DR Pfam; PF12812; PDZ_1; 1.
DR Pfam; PF13180; PDZ_2; 1.
DR Pfam; PF13365; Trypsin_2; 1.
DR PRINTS; PR00834; PROTEASES2C.
DR SMART; SM00228; PDZ; 1.
DR SUPFAM; SSF50156; PDZ domain-like; 1.
DR SUPFAM; SSF50494; Trypsin-like serine proteases; 1.
DR PROSITE; PS50106; PDZ; 1.
PE 3: Inferred from homology;
KW Hydrolase {ECO:0000256|ARBA:ARBA00022801};
KW Protease {ECO:0000256|ARBA:ARBA00022670, ECO:0000313|EMBL:ABR42142.1};
KW Reference proteome {ECO:0000313|Proteomes:UP000000566};
KW Repeat {ECO:0000256|ARBA:ARBA00022737};
KW Serine protease {ECO:0000256|ARBA:ARBA00022825};
KW Signal {ECO:0000256|ARBA:ARBA00022729, ECO:0000256|SAM:SignalP}.
FT SIGNAL 1..21
FT /evidence="ECO:0000256|SAM:SignalP"
FT CHAIN 22..507
FT /evidence="ECO:0000256|SAM:SignalP"
FT /id="PRO_5002696707"
FT DOMAIN 332..386
FT /note="PDZ"
FT /evidence="ECO:0000259|PROSITE:PS50106"
FT ACT_SITE 141
FT /note="Charge relay system"
FT /evidence="ECO:0000256|PIRSR:PIRSR611782-1"
FT ACT_SITE 171
FT /note="Charge relay system"
FT /evidence="ECO:0000256|PIRSR:PIRSR611782-1"
FT ACT_SITE 250
FT /note="Charge relay system"
FT /evidence="ECO:0000256|PIRSR:PIRSR611782-1"
FT BINDING 141
FT /ligand="substrate"
FT /evidence="ECO:0000256|PIRSR:PIRSR611782-2"
FT BINDING 171
FT /ligand="substrate"
FT /evidence="ECO:0000256|PIRSR:PIRSR611782-2"
FT BINDING 248..250
FT /ligand="substrate"
FT /evidence="ECO:0000256|PIRSR:PIRSR611782-2"
SQ SEQUENCE 507 AA; 53791 MW; 26E2D24E1944A511 CRC64;
Query Match 99.8%; Score 2440; Length 507;
Best Local Similarity 99.8%;
Matches 482; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2 TSTYLMNKNQRPAELASGVENTFKQPYRLTNYGTVAAENIDFTTAAESAIHGVVHIKATA 61
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 25 TSTYLMNKNQRPAELASGVENTFKQPYRLTNYGTVAAENIDFTTAAESAIHGVVHIKATA 84
Qy 62 NAQASNGDGGQQYMDPFEYFFGFGGRGGFQRPQQQPRVGAGSGVIISTDGYIITNNHVID 121
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 85 NAQASNGDGGQQYMDPFEYFFGFGGRGGFQRPQQQPRVGAGSGVIISTDGYIITNNHVID 144
Qy 122 GADELEVTLNDNRKFPAKIIGADPTTDIALIKIEATDLPTIPFGDSEKLKVGEWVLAVGN 181
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 145 GADELEVTLNDNRKFPAKIIGADPTTDIALIKIEATDLPTIPFGDSEKLKVGEWVLAVGN 204
Qy 182 PFNLTSTVTAXIVSAKSRGNIGAGGKDRSKIESFIQTDAAVNPGNSGGALVNTKGELVGI 241
|||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||
Db 205 PFNLTSTVTAGIVSAKSRGNIGAGGKDRSKIESFIQTDAAVNPGNSGGALVNTKGELVGI 264
Qy 242 NTAIYSETGNFAGYSFAVPISIAGKVANDLKQFGTVQRAVLGVLIQDPQYVPDAEKEKVK 301
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 265 NTAIYSETGNFAGYSFAVPISIAGKVANDLKQFGTVQRAVLGVLIQDPQYVPDAEKEKVK 324
Qy 302 VFEGAYVGGFAERSSAKEAGIEKGDVIVAVNGVKIKSSSALQEQISKYRPGDKVELTINR 361
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 325 VFEGAYVGGFAERSSAKEAGIEKGDVIVAVNGVKIKSSSALQEQISKYRPGDKVELTINR 384
Qy 362 NGSTKKFTVELRNAQGSTKVVKGGDSAEVMGAAFKALNDEQKRKLGVSYGIEVTGLTSGK 421
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 385 NGSTKKFTVELRNAQGSTKVVKGGDSAEVMGAAFKALNDEQKRKLGVSYGIEVTGLTSGK 444
Qy 422 LKDAGIKKGFIIMIVNNQKISAPEDLEKIVESILQGRTEDQGLFIKGFYPNGRTKYYAID 481
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 445 LKDAGIKKGFIIMIVNNQKISAPEDLEKIVESILQGRTEDQGLFIKGFYPNGRTKYYAID 504
Qy 482 LAE 484
|||
Db 505 LAE 507